Second-generation (non-sedating) antihistamine — H1 antagonist
Pregnancy: Use with caution — limited data; loratadine has more human safety data and is generally preferred.
Fexofenadine 120mg / 180mg Tablets
Brand names: Telfast
Adult dose
Dose: 120 mg once daily (seasonal allergic rhinitis) or 180 mg once daily (chronic urticaria)
Route: Oral
Frequency: Once daily
Max: 180 mg/day
Seasonal allergic rhinitis: 120 mg once daily. Chronic idiopathic urticaria: 180 mg once daily. Truly non-sedating (does not cross blood-brain barrier). Take on empty stomach — food and fruit juices reduce absorption. Avoid grapefruit, orange, and apple juice within 4 hours.
Paediatric dose
Route: Oral
Frequency: Once daily
Max: 120 mg/day
6–11 years: 30 mg twice daily (suspension if available). 12 years and over: adult dose (120 mg OD for AR; 180 mg OD for urticaria). Paediatric suspension not widely available in UK — check unlicensed availability.
Dose adjustments
Renal
Starting dose of 60 mg once daily if eGFR <80 mL/min/1.73m².
Hepatic
No specific dose adjustment recommended.
Clinical pearls
- Truly non-sedating — no CNS penetration; does not affect driving or cognitive function
- Preferred over cetirizine/loratadine for patients where drowsiness is a significant concern (pilots, shift workers)
- Must be taken with water — fruit juices significantly reduce absorption
- BSACI guidelines allow up to 4× standard dose in refractory chronic urticaria under specialist supervision
- Active metabolite of terfenadine (now withdrawn) — fexofenadine lacks terfenadine's cardiac QTc risk
Contraindications
- Hypersensitivity to fexofenadine or terfenadine
- Severe renal impairment (use reduced dose)
Side effects
- Headache
- Nausea
- Dizziness (rare)
- Drowsiness (much less than first-generation antihistamines)
- Fatigue
Interactions
- Antacids (aluminium/magnesium hydroxide) — reduce fexofenadine absorption; separate by 2 hours
- Fruit juices (grapefruit, orange, apple) — reduce bioavailability by up to 36%; take with water
- Erythromycin and ketoconazole — increase fexofenadine plasma levels (clinical significance uncertain)
Monitoring
- Symptom response (TNSS score for rhinitis)
- Drowsiness assessment
Reference: BNFc; BNF; ARIA Guidelines; BSACI Allergic Rhinitis; Telfast SPC. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020